Adebrelimab, chemotherapy and radiotherapy for HER2-negative breast cancer spread to brain
Tests adebrelimab plus chemotherapy and radiotherapy in brain-spread HER2-negative breast cancer.
Key facts
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 102 people, planned
- Started
- 1 Mar 2025
- Expected to end
- 10 Sept 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy
- Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Record updated
- 10 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced HER2-negative breast cancer that has spread to the brain. All get adebrelimab with VEX pill chemotherapy, plus brain radiotherapy given either at the same time or later.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Metastatic breast cancer that has spread to the brain. At least one brain tumour of 10 mm or more must be measurable on MRI. The brain tumours must not need local treatment right away. ECOG performance status 0 or 1, meaning fully active or only slightly limited.
- Earlier treatment
- No more than one line of chemotherapy since the cancer spread. People must not have had brain radiotherapy before, or must not have had brain surgery, unless the operated area is not the radiotherapy target or the cancer came back there. Earlier anthracycline or taxane treatment is allowed. People who had anti-PD-1, anti-PD-L1, anti-PD-L2 or similar immune drugs (such as CTLA-4, OX40, CD137) cannot join.
- Biomarker or test result
- HER2-negative, according to ASCO/CAP guidelines
Main reasons for not taking part
- Cancer spread to the lining of the brain and spinal cord (leptomeningeal metastasis), suspected or confirmed
- Unable to swallow tablets, or stomach or bowel problems that affect absorbing pills
- Active autoimmune disease treated in the past 2 years, weakened immune system, or steroid or immune-suppressing drugs within 7 days before treatment
- Serious heart disease, or heart pumping (LVEF) below 50% or below the normal limit
- HIV, hepatitis B, active hepatitis C, active tuberculosis, or being pregnant or breastfeeding
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Males or females who are at least 18 years of age on the day of signing the informed consent form
- Patients with metastatic HER2-negative breast cancer brain metastasis, with clear clinical documentation; specific criteria refer to the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)
- Patients who have received no more than one line of chemotherapy during the metastatic stage of breast cancer
- Patients with brain metastasis should not require immediate local therapy during the trial and meet at least one of the following criteria:; The patient has not previously received intracranial radiotherapy; The patient has not previously undergone surgery for intracranial metastases; if surgery was performed, the surgical lesion is not the target for the planned radiotherapy, or it is the target lesion and has recurred after surgery
- The patient must have at least one measurable intracranial lesion, with the longest diameter baseline accurately measurable by magnetic resonance imaging (MRI) as ≥10 mm and suitable for precise repeated measurement according to RECIST 1.1 in combination with RANO criteria. Measurable extracranial lesions are not required
- Patients with suspected or confirmed leptomeningeal metastasis should be excluded
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, assessed within 10 days before the start of study treatment
- Patients may have previously received anthracycline (e.g., doxorubicin, epirubicin) and/or taxane (e.g., paclitaxel, docetaxel) therapy, specifically including:; Before breast cancer recurrence, the patient received anthracycline and/or taxane during adjuvant or neoadjuvant treatment; The patient experienced treatment failure during or after anthracycline and/or taxane-based chemotherapy; In the judgment of the investigator, the patient is not suitable for anthracycline and/or taxane-based chemotherapy as a first-line treatment regimen
- Female patients are not pregnant, not breastfeeding, and agree to use necessary contraceptive measures
- The patient is able to sign the informed consent form to participate in the study
- The patient has adequate organ function, as detailed in Table 1 of the study protocol; all screening laboratory tests should be completed within 10 days before the start of study treatment
Who cannot take part
- If the patient has concurrent brain metastasis, the neurological symptoms are too severe to cooperate with radiotherapy
- Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or targeted drugs acting on another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137)
- Diagnosis of immunodeficiency or receiving long-term systemic corticosteroid therapy (daily dose exceeding 10 mg prednisone equivalent) or any form of immunosuppressive therapy within 7 days before the first dose of study treatment
- Malabsorption syndrome, or the disease significantly affects gastrointestinal function; or after subtotal gastrectomy, or after proximal small bowel resection, which may affect the absorption of oral metronomic chemotherapy agents
- Known history of another invasive malignancy that is progressing or requires active treatment within the past 5 years. (Subjects with a history of cutaneous basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ of the breast treated with curative intent, or in situ cervical cancer are not excluded.)
- Active autoimmune disease requiring systemic treatment within the past 2 years (e.g., use of disease-modifying drugs, corticosteroids, or immunosuppressive agents)
- History of pneumonia requiring steroid treatment (non-infectious) or current pneumonia
- Active infection requiring systemic treatment
- Known history of active tuberculosis
- Other significant cardiac disease, such as: myocardial infarction, acute coronary syndrome, or history of coronary artery angioplasty/stent placement/bypass surgery within the past 6 months; New York Heart Association (NYHA) Class II-IV congestive heart failure (CHF) or history of NYHA Class III or IV CHF
- Known history of human immunodeficiency virus (HIV) infection
- Known history of hepatitis B (defined as positive hepatitis B surface antigen [HBsAg]) or known active hepatitis C virus infection (defined as detectable HCV RNA [qualitative])
- Echocardiogram performed at screening confirms left ventricular ejection fraction (LVEF) <50% or below the institutional lower limit of normal
- The subject has leptomeningeal metastasis
- The subject has dysphagia or is unable to swallow tablets
- Positive urine pregnancy test within 72 hours before the first dose of study treatment
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
The 2 groups in the trial
- Experimental Group (Concurrent Radiotherapy)Treatment being tested
1. Adebrelimab: 1200 mg on Day 1, every 3 weeks (q3w). 2. VEX Metronomic Chemotherapy: 1\) Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). 2) Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). 3) Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w). 3. Radiotherapy: The interval between radiotherapy and immunotherapy should be within 3 weeks, with no specific order required. Different radiotherapy techniques will be selected based on the size and location of the metastatic lesions: 1. Stereotactic Body Radiation Therapy (SBRT), 2. Spatially Fractionated Radiation Therapy (SFRT), 3. Low-dose Radiotherapy (LDRT).
Treatment: Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy
- Control Group (Delayed Radiotherapy)Existing treatment, for comparison
1. Adebrelimab: 1200 mg on Day 1, every 3 weeks (q3w). 2. VEX Metronomic Chemotherapy: 1\) Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). 2) Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w). 3. Radiotherapy: If there is intracranial disease progression but extracranial disease remains stable, the systemic treatment regimen of Adelumab + VEX metronomic chemotherapy will be continued, with the addition of intracranial radiotherapy. If there is intracranial disease progression and extracranial disease progression, the systemic treatment regimen will be modified, with the addition of intracranial radiotherapy. The radiotherapy positioning and techniques will be the same as those used in the experimental group.
Treatment: Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
- Plain-language title
- Adebrelimab, chemotherapy and radiotherapy for HER2-negative breast cancer spread to brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 10 June 2026